Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Dialysis

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

JACC. Advances·2026

Same author

A preclinical study of combined hepatic and renal artery denervation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2025

Same author

Changes in blood pressure after crossover to ultrasound renal denervation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2025

Same author

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.

Hypertension research : official journal of the Japanese Society of Hypertension·2024

Same author

Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta-Analysis.

Journal of the American Heart Association·2024

Same author

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.

Circulation·2023

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Renal Denervation: Patient Selection and When to Refer.

Raven A Voora¹, Michael J Bloch², Naomi Dl Fisher³

¹Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina.

The American Journal of Cardiology

|June 11, 2025

Summary

The US FDA approved renal denervation for hypertension in 2023. Most patients experienced significant blood pressure reduction, guiding selection for this new treatment.

Keywords:

hypertension patient referral patient selection renal denervation

More Related Videos

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

Related Experiment Videos

Last Updated: Jun 13, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

Area of Science:

Cardiovascular Medicine
Interventional Cardiology

Background:

Hypertension remains a leading global health concern.
Resistant hypertension poses significant challenges in patient management.
The US Food and Drug Administration (FDA) approved renal denervation in November 2023.

Purpose of the Study:

To review current data on patient selection for renal denervation.
To provide guidance on referring patients with uncontrolled hypertension for this therapy.

Main Methods:

Systematic review of clinical trial data.
Analysis of patient outcomes following renal denervation procedures.
Evaluation of different denervation methodologies.

Main Results:

Most patients achieved clinically significant blood pressure reduction post-procedure.
Variability in response observed across different patient cohorts and methodologies.
Identification of key factors influencing treatment success.

Conclusions:

Renal denervation is a promising therapeutic option for select patients with uncontrolled hypertension.
Careful patient selection is crucial for optimizing outcomes.
Further research is needed to refine patient selection criteria and long-term efficacy.